MDNews - Eastern Pennsylvania/Northwest New Jersey

November/December 2013

Issue link: https://viewer.e-digitaledition.com/i/205749

Contents of this Issue

Navigation

Page 10 of 19

+++++++++++++++++++++++++++++++++++++++ +++ + +++ Í GASTROENTEROLOGY SPOTLIGHT + +++++++++++++++++++++++++++++++++++++++ Colorectal Surgeon Performing New Treatments for Fecal Incontinence By Laura B. Teter ACCORDING TO A NATIONAL INSTITUTES OF HEALTH-FUNDED STUDY APPEARING IN THE JOURNAL GASTROENTEROLOGY, APPROXIMATELY 18 MILLION — OR ONE IN 12 — U.S. ADULTS HAVE FECAL INCONTINENCE (FI). OTHER SOURCES ESTIMATE FI PREVALENCE IS CLOSER TO ONE IN 10 ADULT AMERICANS. LIFESTYLE CHANGES, SUCH AS WEIGHT LOSS AND EXERCISE, MAY AID IN PREVENTION OF FI. FOR MORE SEVERE CASES, NEWER TREATMENT OPTIONS THAT WILL PROVIDE PATIENTS RELIEF ARE AVAILABLE. DAVID S. BUB, MD, IS AMONG FEW DOCTORS IN THE REGION SPECIALIZING IN NEWER TREATMENT OPTIONS FOR FI SUFFERERS. H ISTORICALLY, DOCTORS WERE reluctant to treat or refer patients for treatment of FI because no options were available except for dietary modification, constipating agents or radical procedures — none of which were truly effective or successful. Moreover, patient disclosure was often avoided due to the stigma associated with this disorder. Dr. Bub, board-certified colon and rectal surgeon, is one of a select few physicians in the region performing two newly approved treatments and providing hope to those suffering from this affliction. In 2011, the U.S. Food and Drug Administration approved two new minimally invasive treatment methods for fecal incontinence. The Medtronic InterStim Therapy System uses an implantable neurostimulator — similar to a pacemaker — that emits a continuous mild electrical pulse through a wire to stimulate the sacral nerves, which strengthens the sphincter. This system has been a standard treatment for urinary incontinence since 1997 and was approved in 2011 to treat fecal incontinence. The minimally invasive outpatient procedure is performed under sedation and provides the patient better outcomes than previous more invasive surgical treatments. Prior to implantation under the skin, the neurostimulator is tested externally for one to two weeks, along with analysis of the patient's bowel diary to measure results. If the response is positive, the neurostimulator (InterStim) is implanted. Results from the InterStim Therapy for Bowel Control Prospective Clinical Study suggest that when the stimulator was placed in the best location, roughly 75 percent of patients showed improvement with InterStim. Of that 75 percent, 40 percent regained complete continence at 12 months. A second new treatment option is available for patients who failed conservative therapy. Solesta is a tissue bulking agent also approved by the FDA in 2011. Developed as a minimally invasive treatment for fecal incontinence, Solesta is injected in the anal canal in an outpatient setting without the need for anesthesia. Solesta aids in the remedy of fecal incontinence by David S. Bub, MD narrowing the anal canal, which allows for better sphincter control. Studies show more than 50 percent of patients utilizing Solesta experience a 50 percent reduction in incidents of fecal incontinence. Solesta can provide long-lasting results that have been shown to last as long as two years with one or two treatments. Dr. Bub suggests that fecal incontinence is more common than most people think. Millions of people suffer from regular accidents that leaks, limiting their day-to-day activities and dramatically affecting their quality of life. Although widespread, FI is not a natural part of aging — it is a treatable medical problem. "With the aid of these two new treatment options, patients no longer need to suffer in silence and no longer have to fear major medical procedures," Dr. Bub says. He encourages physicians to give their patients questionnaires to complete. The questionnaires allow patients to discreetly provide information about their symptoms, enabling their physicians to assess whether a referral is necessary. Until two years ago, nothing like these options was available. Prior to 2011, the available surgical procedures were highly invasive, high-risk, and with much higher complications and poor durability. Dr. Bub asserts, "Today we can treat fecal incontinence less invasively with much better outcomes and dramatically improve patients' lives." David S. Bub, MD, is a board-certified colon and rectal surgeon practicing in eastern Pennsylvania. He is co-author of 100 Questions & Answers About Colorectal Cancer. Dr. Bub received his degree from the New York University School of Medicine and performed his clinical research fellowship at Memorial Sloan-Kettering Cancer Center and his surgical fellowship at Greater Baltimore Medical Center. He holds appointments at Lehigh Valley Health Network, Sacred Heart Hospital, and St. Luke's University Health Network. For more information about fecal incontinence or colorectal conditions, please email info@allentowncolonrectal.com or call 610-433-7571. I MDNEWS.COM I MD NEWS Eastern Pennsylvania/NW New Jersey | 11

Articles in this issue

Links on this page

Archives of this issue

view archives of MDNews - Eastern Pennsylvania/Northwest New Jersey - November/December 2013